Featuring perspectives from Prof Solange Peters and Drs Zofia
Piotrowska and Gregory J Riely, including the following topics:
Current and Future Treatment of Non-Small Cell Lung Cancer
(NSCLC) with Targetable Mutations, Including ALK and ROS1
Introduction: Targeted treatment in the adjuvant setting
(0:00)
Case: A man in his late 60s with metastatic adenosquamous
carcinoma of the lung — PD-L1 >95%, ROS1 rearrangement —
Margaret Deutsch, MD (11:55)
Case: A woman in her mid-70s with metastatic adenocarcinoma of
the lung and cancer in the right breast — TMB 14 mut/Mb, ALK
mutation — Raymond Lobins, DO (19:15)
Management Strategies for Patients with NSCLC with RET Fusions
or MET Alterations
Case: A woman in her early 60s with metastatic adenocarcinoma
of the lung — PD-L1 0%, RET KIF5B fusion — Mohamed K Mohamed, MD,
PhD (24:40)
Key Data Guiding the Management of Metastatic NSCLC with EGFR
Mutations
Case: A woman in her mid-60s with metastatic adenocarcinoma of
the lung — PD-L1 60%, EGFR exon 19 deletion — Gigi Chen, MD
(29:15)
Case: A man in his early 70s with metastatic NSCLC — EGFR L858R
mutation — Maria Regina Flores, MD (36:53)
Therapeutic Approaches for Patients with NSCLC with HER2 or
KRAS Mutations
Case: A woman in her early 60s with recurrent metastatic
adenocarcinoma of the lung — HER2 mutation — Dr Lobins (43:20)
Case: A woman in her mid-40s with metastatic adenocarcinoma of
the lung — KRAS G12C mutation — Sulfi Ibrahim, MD (51:03)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.